1. HDAC5 inhibition attenuates ventricular remodeling and cardiac dysfunction.
- Author
-
Zhu, Chenxi, Piao, Zhehao, and Jin, Li
- Subjects
- *
VENTRICULAR remodeling , *HEART diseases , *EXTRACELLULAR signal-regulated kinases , *ANGIOTENSIN II , *HISTONE deacetylase , *CARDIAC hypertrophy , *CELLULAR signal transduction - Abstract
Background: This study aimed to investigate the role of histone deacetylase 5 (HDAC5) in ventricular remodeling and explore the therapeutic potential of the HDAC5 inhibitor LMK235. Methods: A transverse aortic constriction (TAC) mouse model and angiotensin II (Ang II)-treated H9C2 cells were used to evaluate the effects of HDAC5 inhibition with LMK235 on ventricular remodeling and cardiac dysfunction. Additionally, the involvement of the extracellular signal-regulated kinase (ERK)/early growth response protein 1 (EGR1) signaling pathway in regulating myocyte enhancer factor 2 A (MEF2A) expression was assessed. Results: HDAC5 was upregulated in TAC mice and Ang II-treated H9C2 cells, suggesting its involvement in ventricular remodeling and cardiac dysfunction. LMK235 treatment significantly improved cardiac function in TAC mice and attenuated TAC-induced ventricular remodeling and Ang II-induced H9C2 cell hypertrophy. Mechanically, HDAC5 inhibition activated the ERK/EGR1 signaling pathway. Conclusions: Our findings demonstrate that HDAC5 may suppress the activation of ERK/EGR1 signaling to regulate MEF2A expression and therefore participate in cardiac pathophysiology. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF